Chinese Startup Synyi AI Trials First AI Doctor Clinic in Saudi Arabia in 2025
Chinese Startup Synyi AI Trials First AI Doctor Clinic in Saudi Arabia in 2025
AL-AHSA, Saudi Arabia—Synyi AI, a Shanghai-based medical technology firm, has launched the world’s first known clinic where artificial intelligence serves as the primary diagnosing agent, with human doctors reviewing treatment plans only after consultations. The pilot program, which began in April 2025 in Saudi Arabia’s Al-Ahsa region in partnership with Almoosa Health Group, advances Saudi Arabia’s Vision 2030 goal to modernize healthcare through advanced technology.
The clinic employs an AI system named Dr. Hua, which independently conducts patient consultations. Patients enter symptoms on a tablet, and Dr. Hua asks follow-up questions while analyzing medical data, such as X-rays or cardiograms, with assistance from human staff. After each consultation, Dr. Hua generates a treatment plan, which a human doctor verifies remotely. On-site physicians are available for emergencies the AI cannot address, though specific protocols for these situations remain undisclosed.
Synyi AI claims Dr. Hua achieved a company-reported error rate of less than 0.3% in internal pre-trial testing, though details on testing methodology, sample size, or comparisons with human doctor error rates are not available. “We’re enabling AI to directly diagnose and treat patients,” said Zhang Shaodian, Synyi AI’s chief executive. The clinic, currently free during its trial phase, focuses on approximately 30 respiratory conditions, including asthma and pharyngitis, with plans to expand to 50 diseases, covering gastrointestinal and dermatological conditions, by 2026. Data collected will be submitted for Saudi regulatory approval to enable commercial operations.
Founded in 2016, Synyi AI has collaborated with over 800 hospitals and medical institutions in China, deploying AI for diagnostics, data management, and research. Supported by investors including Tencent Holdings Ltd., Hongshan Capital, and GGV Capital, the company is entering Saudi Arabia as its first international market. Synyi AI is in discussions with other Saudi hospitals to expand the model.
The clinic aims to enhance healthcare access, particularly in underserved areas, by streamlining routine consultations. Automation of routine tasks may reduce costs, though significant upfront investment is required. While specific public opinion data on the clinic is unavailable, concerns about diagnostic accuracy, data privacy, and the lack of human empathy in AI-driven care are noted as common issues in similar initiatives.
Saudi Arabia may need to develop or adopt clear regulatory frameworks to address data security and diagnostic reliability in AI healthcare, though details on current or proposed regulations are not specified. If successful, the Al-Ahsa clinic may serve as a model for future AI integration in clinical settings, particularly in regions with limited medical resources. The partnership between Synyi AI and Almoosa Health Group underscores the potential of international collaboration in advancing healthcare technology.
More info here – Have a Story? Address it to the Editor and submit it here
Featured image Copyright Bloomberg
Disclaimer
The information provided in this article is for general informational purposes only and from publicly available sources. While we strive for accuracy, we do not make any representations or warranties, express or implied, regarding the completeness, reliability, or validity of the content. This article does not make any direct claims about specific companies, individuals, or organizations. Any references to reports or external sources are for context and do not imply endorsement or verification of any specific allegations. Readers are encouraged to conduct their own research and seek professional advice before making business decisions. We disclaim any liability for any losses or damages incurred as a result of reliance on the information provided.